PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.66
Negative D/E while Biotechnology median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
-22.06
Net cash position versus Biotechnology median net debt of 1.34. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-2.24
Negative coverage while Biotechnology median is -1.40. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
0.01
Current ratio below 50% of Biotechnology median of 2.24. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.